Comparing the current results to its competitors, Axim Biotechnologies Inc reported Revenue increase in the 2 quarter 2024 by 76.04 % year on year. The sales growth was above Axim Biotechnologies Inc 's competitors' average revenue growth of 19.38 %, achieved in the same quarter.
Axim Biotechnologies Inc 's Comment on Competition and Industry Peers
The company acquired technology and intellectual property from Advanced Tear, which requires other companies to submit a new 510(k) application and conduct clinical trials to manufacture similar diagnostic devices. The company anticipates demand for its MMP-9 quantitative test pending FDA 510(k) clearance. Its competitive landscape includes commercial pharmaceutical and biotechnology companies, academic institutions, government agencies, and private and public research organizations. Competitors may develop products that are safer, more effective, or less expensive, potentially impacting the company's market opportunities. Many competitors possess greater financial resources and expertise in research, development, manufacturing, clinical trials, regulatory approvals, and marketing. Smaller or early-stage companies may also pose competition, particularly through partnerships with larger firms. Competition also exists in recruiting and retaining qualified scientific and management personnel. Advanced Tear is identified as a competitor in company filings.
Due to outstanding performance in Overall company, revenue grew by 76.04 % Axim Biotechnologies Inc improved its market share, to approximately 0.01 %.
Gb Sciences Inc uses a business model that focuses on the development of plant-based medicine and therapies using their proprietary growing techniques and advanced research and development capabilities. They aim to leverage their expertise in plant genetics, cultivation, and extraction to create innovative and effective solutions for the medical industry while pursuing strategic partnerships and licensing opportunities.
Innovative Industrial Properties Inc's business model revolves around acquiring and managing properties used for the cultivation and processing of medical cannabis. They lease these properties to licensed operators in the cannabis industry, providing a reliable source of recurring rental income.
Tilray Brands Inc operates as a cannabis-focused consumer packaged goods company. They develop and market a range of cannabis products, including dried flower, oils, capsules, and beverages, catering to medical and recreational users. With a focus on innovation and brand-building, Tilray Brands Inc aims to establish a strong presence in the cannabis industry and deliver high-quality products to its customers.
Sources:
Axim Biotechnologies Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Axim Biotechnologies Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
